Affiliation:
1. Greater Vancouver Mental Health Service Society
2. West Side Team, GVMHSS
3. St. Vincent's Hospital And University Of British Columbia
4. St. Vincent's Hospital
Abstract
Objective: to Compare the Efficacy and Side Effects of Risperidone in Younger Adult and Geriatric Patients. Methods: Open Retrospective Study of 102 Consecutive Intakes, prescribed risperidone, by a mental health team. All patients were non-hospitalized community residents. Prior to initiation of risperidone, and at termination of study period, Clinical Global Impression (CGI) scores were used to track progress. Variables monitored were: concurrent use of other antipsychotics, compliance, side effects, and maintenance dosage. Results: The most common DSM-IV diagnoses were schizophrenia in the younger adult group and late onset delusional disorders in the geriatric group. Compliance was good for both groups. The geriatric group demonstrated a greater treatment response which was reached at a significantly lower dosage. There was no statistically significant difference in the occurrence of side effects. Examination of response by diagnostic category indicated that geriatric patients with late onset delusional disorder showed the best response while adults with either schizophrenia or affective syndromes also showed positive response. Conclusions: Risperidone, at lower than recommended doses, shows promise in the treatment of late onset delusional disorders and behavior syndromes of dementia. The side effect profile was benign, as was suggested by experience in treating schizophrenia. Scientifically more rigorous prospective studies for the indications and efficacy of risperidone in late onset psychotic disorders and psychoses and behavior syndromes associated with dementing illness are overdue.
Subject
Psychiatry and Mental health
Reference20 articles.
1. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations
2. Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus Haloperidol
3. A Canadian Multicenter Placebo-Controlled Study of Fixed Doses of Risperidone and Haloperidol in the Treatment of Chronic Schizophrenic Patients
4. Prado P, Kramer-Ginsberg E, Kremen N, Hanan P, Safferman AZ. Risperidone in dementia with behavioural disturbances. 148th Meeting of the American Psychiatric Association 1995, May 20–25, Miami, Florida, p. 55.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献